REPLY Brings Quantum Computing Into Practice
Reply is part of the research project "Bench-QC", which stands for application-driven benchmarking of quantum computing. The focus of the project, which is funded by the Bavarian State Ministry of Economic Affairs, Regional Development and Energy, is the practical usability of quantum computing in industrial applications. The initiative, consisting of industrial partners and Fraunhofer institutes, specifically identifies the applications for which quantum computing can provide a benefit to companies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230914964363/en/
The goal of the Bench-QC project is to investigate when quantum computers produce better results than classic high-performance computers. Reply has the role of consortium leader and is bringing in already implemented use cases in various industries in the field of quantum-inspired optimization. (Photo: Reply)
Reply has the role of consortium leader and is bringing in already implemented use cases in various industries in the field of quantum-inspired optimization. Reply has developed an efficient classical solver for QUBO (quadratic unconstrained binary optimization) problems: the Reply tool "MegaQUBO" finds solutions for tens of thousands of variables within seconds. Reply's reference implementation for hybrid neural networks is also included in the benchmarking project.
Filippo Rizzante, CTO at Reply, commented: "We are very excited to bring quantum computing into practice. With this initiative, we want to bring academic discussions to the business world and show companies how they can use quantum computing commercially and the benefits they can derive from it. That is why we have developed quantum-inspired algorithms that allow us to describe and optimize complex situations, giving companies time and cost savings".
In addition to Reply, the project partners include BMW, and the two Fraunhofer institutes for Integrated Circuits IIS, and for Cognitive Systems IKS. The lighthouse project, scheduled for three years, is part of the Munich Quantum Valley of the Bavarian state government, and aims to establish expertise in quantum computing and quantum technologies in Bavaria.
Reply
Reply [EXM, STAR: REY] specialises in the design and implementation of solutions based on new communication channels and digital media. As a network of highly specialised companies, Reply defines and develops business models enabled by the new models of AI, big data, cloud computing, digital media and the internet of things. Reply delivers consulting, system integration and digital services to organisations across the telecom and media; industry and services; banking and insurance; and public sectors. www.reply.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230914964363/en/
Contact information
Media contacts:
Reply
Fabio Zappelli
f.zappelli@reply.com
Tel. +390117711594
Sandra Dennhardt
s.dennhardt@reply.com
Tel. +49 170 4546229
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF and BASF Announce Strategic Collaboration to Drive Next-Generation Enzyme and Polymer Innovation21.10.2025 13:00:00 EEST | Press release
IFF (NYSE: IFF) — a global leader in flavors, fragrances, food ingredients, health and biosciences — announced a strategic collaboration with BASF, one of the world’s largest chemical companies and leader in sustainable product innovation, to accelerate the development of IFF’s Designed Enzymatic Biomaterials™ technology platform and create next-generation enzyme technologies for fabric, dish and personal care as well as industrial cleaning applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021911702/en/ Photo credit: IFF This collaboration brings together two industry leaders with a shared vision: to develop high-performance, sustainable solutions that meet evolving consumer and market demands. By combining advanced chemical capabilities and expertise in biotechnology and protein engineering from IFF and BASF, the partnership aims to deliver breakthrough solutions at scale that enhance cleaning performance, imp
Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule21.10.2025 12:12:00 EEST | Press release
Spanish international pharmaceutical company Ferrer has announced the completion of patient recruitment for the PROSPER study, a Phase II clinical trial designed to assess the efficacy, safety, and pharmacokinetics of FNP-223, an orally available, potent and selective inhibitor of the OGA enzyme, in-licensed from Asceneuron, aimed at slowing disease progression in Progressive Supranuclear Palsy (PSP)1. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251021806533/en/ Ferrer's pharmaceutical production plant in Sant Cugat del Valles, Barcelona, Spain. PSP is a rare, rapidly progressive and ultimately fatal neurodegenerative disease2. To date, no disease-modifying therapies have been approved for PSP. The PROSPER study is a randomized, double-blind, placebo-controlled trial3 that has successfully recruited the planned number of 220 participants with PSP in just 14 months, achieving this milestone on October 6th, two months ahead
Polpharma Biologics announces commercial launch of Europe’s first Pre-filled Syringe presentation of a ranibizumab biosimilar21.10.2025 11:51:00 EEST | Press release
Polpharma Biologics today announced Ranivisio® PFS (ranibizumab biosimilar pre-filled syringe), is now commercially available in France. Ranivisio® is the first Lucentis® biosimilar which is offered in a convenient pre-filled syringe (PFS) presentation in Europe, setting a new standard for affordable biologics in ophthalmic care. This innovative configuration provides precise dosing and ease of use, supporting efficient administration for patients with neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Bioeq AG, a joint venture between Polpharma Biologics Group BV and Formycon AG, is responsible for the development and licensing of Ranivisio® PFS. Teva holds the commercialization rights for France under an exclusive licensing agreement with Bioeq. The drug substance for Ranivisio® PFS is manufactured by Polpharma Biologics S.A. - a contract development and manufacturing organization (CDMO) operating under the Rezon
NTT DATA Strengthens Global Insurance Leadership with Acquisition of Alchemy Technology Services21.10.2025 11:00:00 EEST | Press release
NTT DATA, a global leader in AI, digital business and technology services, today announced the acquisition of Alchemy Technology Services, a specialist insurance technology consultancy. The move reinforces NTT DATA’s commitment to transforming the global insurance ecosystem, addressing current and emerging challenges around agility, modernization and scalability. In addition to its strong consultancy and Guidewire credentials, Alchemy brings deep expertise in the specialty insurance market, particularly in supporting complex and regulated environments, such as the London Market, the largest (re)insurance subscription market globally. This will further strengthen NTT DATA’s ability to serve niche and high-value segments across the global insurance landscape. A shared vision for insurance innovation This acquisition marks a significant milestone in NTT DATA’s strategy to lead the digital reinvention of the insurance sector - a market set to reach $230.7 billion in IT spend this year. Bui
Impartner Expands European Infrastructure to Accelerate Growth and Customer Support Across EMEA21.10.2025 11:00:00 EEST | Press release
Impartner, the leading provider of Partner Relationship Management (PRM) solutions, today announced the expansion of its European infrastructure with a new Azure-based data centre in the Netherlands. This milestone reflects Impartner’s accelerating success across the EMEA region and its commitment to providing customers with the highest levels of security, compliance, performance and support. “Our EMEA business continues to grow rapidly as companies across the region look to Impartner to scale their partner ecosystems,” said Curtis Brinkerhoff, CRO of Impartner. “Expanding our infrastructure within Europe, in close collaboration with Microsoft, ensures we are not only meeting strict EU data residency and privacy standards, but also strengthening performance and responsiveness for our customers across all industries.” By hosting in Microsoft’s Netherlands Azure data centre, Impartner customers benefit from the assurance of GDPR-compliant data handling, best-in-class security and the spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom